aTYR PHARMA (ATYR) Price to Sales (2019 - 2025)

aTYR PHARMA's (ATYR) quarterly Price to Sales came in at 372.04 in Q3 2025, down 34.41% quarter-over-quarter from 567.19 in Q1 2024.

Analysis

aTYR PHARMA (ATYR) Price to Sales (2019 - 2025) Analysis & Trends

aTYR PHARMA (ATYR) has reported Price to Sales for 6 consecutive years, with 372.04 the latest figure, recorded in Q3 2025.

For the quarter ending Q3 2025, Price to Sales changed N/A year-over-year to 372.04; the trailing twelve-month figure through Mar 2026 stood at 402.53 (changed N/A YoY), and the FY2025 full-year result was 404.04, down 68.79% from the prior year.
Price to Sales retreated to 372.04 in Q3 2025 per ATYR's latest filing, from 567.19 in the prior quarter.
Across five years, Price to Sales topped out at 567.19 in Q1 2024 and bottomed at 6.22 in Q4 2022.
Historically, Price to Sales has averaged 301.89 across 4 years, with a median of 317.07 in 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Amgen	208.48 Bn	194.49 Bn	7.24 Bn
2	Gilead Sciences	186.29 Bn	183.02 Bn	6.22 Bn
3	Vertex Pharmaceuticals	128.79 Bn	120.93 Bn	2.84 Bn
4	Regeneron Pharmaceuticals	80.66 Bn	72.67 Bn	3.93 Bn
5	Moderna	61.46 Bn	56.32 Bn	52.00 Mn
6	Argenx Se	61.28 Bn	56.10 Bn	1.37 Bn
7	Alnylam Pharmaceuticals	32.04 Bn	28.73 Bn	992.69 Mn
8	Biogen	31.84 Bn	30.56 Bn	1.96 Bn
9	Roivant Sciences	28.74 Bn	29.43 Bn	1.16 Mn
10	aTYR PHARMA	35.31 Mn	-22.30 Mn	-

Historic Data

Download Data